TITLE

Genetically predetermined limitation in HaCaT cells that affects their ability to serve as an experimental model of psoriasis

AUTHOR(S)
Soboleva, A.; Zolotarenko, A.; Sobolev, V.; Bruskin, S.; Piruzian, E.; Mezentsev, A.
PUB. DATE
October 2014
SOURCE
Russian Journal of Genetics;Oct2014, Vol. 50 Issue 10, p1081
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Proinflammatory cytokines TNF, IFNG, and IL17 play an important role in eruption of psoriasis. The activation of epidermal keratinocytes with the named cytokines alters their terminal differentiation program and causes their hyperproliferation in the diseased skin. HaCaT cells, which are immortalized human keratinocytes, are often used as a cellular model of psoriasis. The aim of this study was to evaluate changes in gene expression and the proliferation rates in cultured HaCaT cells treated with TNF, IFNG, and IL17. We found that HaCaT cells decrease their proliferation rate in response to either IL17 or a combination TNF and IFNG. The analysis of microarray data discovered a group of 12 genes, which were downregulated in HaCaT after treatments with the named cytokines and upregulated in psoriatic lesional skin. Eight genes were important for DNA replication and they also contributed to two larger networks that regulated cell progression through the cell cycle. We conclude that HaCaT cells have a sufficient limitation as a cellular model of psoriasis due to their treatment with proinflammatory cytokines, namely TNF, IFNG, and IL17 does not increase their proliferation rate. Thus, the studies of psoriasis based on HaCaT cells as an experimental model shall take in account this important phenomenon.
ACCESSION #
99008387

 

Related Articles

  • Pituitary Tumor Transforming Gene 1 Induces Tumor Necrosis Factor-α Production from Keratinocytes: Implication for Involvement in the Pathophysiology of Psoriasis. Ishitsuka, Yosuke; Kawachi, Yasuhiro; Maruyama, Hiroshi; Taguchi, Shijima; Fujisawa, Yasuhiro; Furuta, Junichi; Nakamura, Yasuhiro; Ishii, Yoshiyuki; Otsuka, Fujio // Journal of Investigative Dermatology;Nov2013, Vol. 133 Issue 11, p2566 

    Proliferation and differentiation in the epidermis must be tightly regulated. This regulation is known to involve a range of transcription factors, including pituitary tumor transforming gene 1 (PTTG1), a ubiquitously distributed transcription factor that regulates keratinocyte proliferation and...

  • New biologic drugs get under the skin of psoriasis. Williams, Sarah C P // Nature Medicine;May2012, Vol. 18 Issue 5, p638 

    The article reports on the experimental results of eixekizumab and brodalumab, psoriasis medicines, which target interleukin-17 (IL-17) and its receptor. It says that both agents' phase two data validate IL-17 and offer treatment for people with psoriasis therapy failures. Craig Leonardi,...

  • Inter-Regulation of Th17 Cytokines and the IL-36 Cytokines In Vitro and In Vivo: Implications in Psoriasis Pathogenesis. Carrier, Yijun; Ma, Hak-Ling; Ramon, Hilda E; Napierata, Lee; Small, Clayton; O'Toole, Margot; Young, Deborah A; Fouser, Lynette A; Nickerson-Nutter, Cheryl; Collins, Mary; Dunussi-Joannopoulos, Kyri; Medley, Quintus G // Journal of Investigative Dermatology;Dec2011, Vol. 131 Issue 12, p2428 

    Accumulating evidence indicates that IL-1 family members and Th17 cytokines have a pathogenic role in psoriasis. We investigated the regulatory interactions of the IL-1-like IL-36 cytokine family and the Th17 cytokines in the context of skin inflammation. We observed increased gene expression of...

  • Long-Term Remission after 1 Course of 12 Weeks of Alefacept Therapy – A Case Report. Vitéz, Lilla; Heese, Elisabeth; Wozel, Gottfried // Dermatology (10188665);2005, Vol. 211 Issue 2, p165 

    The article focuses on a case study on long-term remission after one course of 12 week of alefacept therapy to treat psoriasis. Alefacept, efalizumab and tumor necrosis factor-alpha antagonists are available for treating psoriasis. Alefacept has to be applied generally by parenteral route either...

  • Tumor necrosis factor and cancer, buddies or foes? Xia WANG; Yong LIN // Acta Pharmacologica Sinica;Nov2008, Vol. 29 Issue 11, p1275 

    Tumor necrosis factor (TNF) is a multifunctional cytokine that plays important roles in diverse cellular events such as cell survival, proliferation, differentiation, and death. As a pro-inflammatory cytokine, TNF is secreted by inflammatory cells, which may be involved in...

  • VEGI, a new member of the TNF family activates Nuclear Factor-κB and c-Jun N-terminal kinase and modulates cell growth. Haridas, Valsala; Shrivastava, Anju; Su, Jeffrey; Yu, Guo-Liang; Ni, Jian; Liu, Ding; Chen, Su-Fang; Ni, Yansong; Ruben, Steve M; Gentz, Reiner; Aggarwal, Bharat B // Oncogene;11/11/99, Vol. 18 Issue 47, p6496 

    Recently a new member of the human tumor necrosis factor (TNF) family named as VEGI was reported. However, very little is known about the biological activities displayed by this cytokine. In this report, we show that in myeloid cells VEGI activated the transcription factor κB (NF-κB) as...

  • Eiger and its receptor, Wengen, comprise a TNF-like system in Drosophila. Kauppila, Saila; Maaty, Walid S A; Chen, Po; Tomar, Raghuvir S; Eby, Michael T; Chapo, Joe; Chew, Sukit; Rathore, Nisha; Zachariah, Sunny; Sinha, Suwan K; Abrams, John M; Chaudhary, Preet M // Oncogene;7/31/2003, Vol. 22 Issue 31, p4860 

    In mammals, members of the tumor necrosis factor (TNF) family play an important role in the regulation of cellular proliferation, differentiation and programmed cell death. We describe isolation and characterization of an orthologous ligand/receptor axis in Drosophila. The ligand, designated...

  • Defective responsiveness of CD5+ B1 cells to lipopolysaccharide in cytokine production. Koide, Naoki; Morikawa, Akiko; Ito, Hiroyasu; Sugiyama, Tsuyoshi; Hassan, Ferdaus; Islam, Shamima; Tumurkhuu, Gantsetseg; Mori, Isamu; Yoshida, Tomoaki; Yokochi, Takashi // Journal of Endotoxin Research;2006, Vol. 12 Issue 6, p346 

    Previously, we found that mouse TH2.52 cells possess the characteristic of CD5+ B1 cells and proliferate in response to lipopolysaccharide (LPS). The effect of LPS on cytokine production by TH2.52 B1 cells was studied. TH2.52 cells constitutively produced a small amount of tumor necrosis factor...

  • A role for tumor necrosis factor-α in ischemia and ischemic preconditioning.  // Journal of Neuroinflammation;2011, Vol. 8 Issue 1, p87 

    The article focuses on the role for tumor necrosis factor (TNF)-α in ischemia and ischemic preconditioning. The TNF-α activity is mediated through activation of its surface receptors, found on both neuronal and glial cell populations. Due to the complex nature of cross-communication...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics